ALUR · Allurion Technologies, Inc.
Market Cap
$2.01M
Shares
1.00M
Allurion Technologies, Inc. Earnings Call Transcripts
Quarterly earnings calls for Allurion Technologies, Inc. (ALUR), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲13.3%
$18.20M
−$21.63M
'23 Q3
23-11-13
·
$8.24M
−$21.39M
'23 Q4
24-03-21
▼33.3%
$9.39M
$2.00M
'24 Q1
24-05-14
▼9.2%
$11.77M
−$8.32M
'24 Q2
24-08-13
▼70.5%
$5.37M
$8.74M
'24 Q3
24-11-13
▼32.1%
$5.59M
−$9.61M
'24 Q4
25-03-26
▼40.5%
$5.58M
−$1.50M
'25 Q1
25-05-14
▼71.3%
$3.38M
−$9.34M
'25 Q2
25-08-13
LATEST
▼50.5%
$2.66M
−$11.88M
'25 Q3
25-11-12
Earnings call
FY25 · Q3
2025-11-12
Allurion Technologies, Inc. (ALUR) Q3 2025 Earnings Call Transcript
Confident tone
Strategic pivot to combination therapy with GLP-1s
U.S. market launch preparation
FDA approval progress
Revenue
$2.66M
▼ 50.5% YoY Diluted EPS
$-22.95
▼ 145% YoY Gross margin
49.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-13
Allurion Technologies, Inc. (ALUR) Q2 2025 Earnings Call Transcript
Positive tone
R&D pipeline and GLP-1 drug-eluting balloon
Strategic pivot to combination therapy with low-dose GLP-1s
Operating expense reduction and restructuring
Revenue
$3.38M
▼ 71.3% YoY Diluted EPS
$-19.20
Gross margin
73.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-14
Allurion Technologies, Inc. (ALUR) Q1 2025 Earnings Call Transcript
Confident tone
GLP-1 Combination Strategy
FDA Approval Pathway
Path to Profitability
Revenue
$5.58M
▼ 40.5% YoY Diluted EPS
$-4.65
▼ 132.3% YoY Gross margin
74.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-26
Allurion Technologies, Inc. (ALUR) Q4 2024 Earnings Call
Revenue
$5.59M*
▼ 32.1% YoY Gross margin
45.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-13
Allurion Technologies, Inc. (ALUR) Q3 2024 Earnings Call Transcript
Positive tone
Q3 Financial Results and France Recall
GLP-1 Market Impact and Combination Therapy
U.S. FDA Approval and Launch
Revenue
$5.37M
▼ 70.5% YoY Diluted EPS
$51.00
Gross margin
58.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-13
Allurion Technologies, Inc. (ALUR) Q2 2024 Earnings Call Transcript
Balanced tone
France ANSM suspension
GLP-1 competition and positioning
Procedure volume and demand
Revenue
$11.77M
▼ 9.2% YoY Diluted EPS
$-65.10
Gross margin
76.4%
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-14
Allurion Technologies, Inc. (ALUR) Q1 2024 Earnings Call Transcript
Confident tone
Revenue and 2024 guidance
Virtual Care Suite / B2B SaaS
Geographic expansion and AUDACITY FDA trial
Revenue
$9.39M
▼ 33.3% YoY Diluted EPS
$14.40
Gross margin
73.2%
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-21
Allurion Technologies, Inc. (ALUR) Q4 2023 Earnings Call Transcript
Positive tone
GLP-1 drugs as opportunity and headwind
Cost reduction and cash burn
Audacity FDA trial and PMA
Revenue
$8.24M*
Gross margin
78.1%
Rev · 5q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-13
Allurion Technologies, Inc. (ALUR) Q3 2023 Earnings Call Transcript
Revenue
$18.20M
▲ 13.3% YoY Diluted EPS
$-203.40
Gross margin
76.7%
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Showing 1–9 of 9 earnings calls